Epidemiology of breast cancer - Selected highlights

Breast

Volumn 12, Issue 6, 2003, Pages 405-411

  Cuzick, Jack ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Breast cancer; Chemoprevention; Epidemiology; IBIS; Risk factors; Risk profile

Indexed keywords

ANASTROZOLE; EPIDERMAL GROWTH FACTOR; ESTROGEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN; TAMOXIFEN;

ADOLESCENT; ADULT; AGE; ANAMNESIS; BREAST CANCER; CANCER RISK; CHEMOPROPHYLAXIS; ENDOMETRIUM CANCER; FEMALE; GENE MUTATION; GYNECOLOGIC DISEASE; HEREDITY; HIGH RISK PATIENT; HISTOPATHOLOGY; HORMONAL REGULATION; HORMONAL THERAPY; HUMAN; MAMMOGRAPHY; PATIENT CARE; POSTMENOPAUSE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REPRODUCTION; SHORT SURVEY; TUMOR SUPPRESSOR GENE; VASOMOTOR DISORDER; VEIN THROMBOSIS;

EID: 0347519223     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(03)00144-9     Document Type: Article

References (22)

1. Pharoah P D, Day N E, Duffy S, Easton D F, Ponder B A. Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer 1997; 71: 800-809.
2. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58209 women with breast cancer and 101986 women without the disease. Lancet 2001; 358: 1389-1399.
3. Thomas H V, Reeves G K, Key T J. Endogenous estrogens and postmenopausal breast cancer: a quantitative review. Cancer Causes Control 1997; 8: 992-998.
4. Cuzick J, Powles, T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P. Overview of the main outcomes in breast cancer prevention trials. Lancet 2003; 361: 296-300.
5. Warren S. The relation of "chronic mastitis" to carcinoma of the breast. Surg Gynecol Obstet 1940; 71: 257-273.
6. Ernster V. The epidemiology of benign breast disease. Epidemiol Rev 1981; 3: 184-202.
7. Dupont W D, Page D L. Breast cancer risk associated with proliferative disease, age at first birth, and a family history of breast cancer. Am J Epidemiol 1987; 125: 769-779.
8. Wolfe J N, Albert S et al. Breast parenchymal patterns: analysis of 332 incident breast carcinomas. Am J Roentgenol 1982; 138: 113-118.
9. Boyd N F, Byng J W, Jong R A, Fishell E K, Little L E, Miller A B, Lockwood G A, Tritchler D L, Yaffe M J. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Nat Cancer Inst 1995; 87: 670-675.
10. Cuzick J, Berridge D, Whitehead J. Mammographic dysplasia as an entry criterion for breast cancer prevention trials. Lancet 1991; 337: 1225.
11. Gail M H, Brinton L A, Byar D P, Corle D K, Green S B, Schairer C, Mulvihill J J. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Nal Cancer Inst 1981; 81: 1879-1886.
12. Claus E B, Risch N, Thompson W D V. Genetic analysis of breast cancer in the Cancer and Steroid Hormone Study. Am J Hum Genet 1991; 48: 232-242.
13. Tyrer, J, Duffy S W, Cuzick, J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 2003; to appear.
14. The ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359: 2131-2139.
15. Cuzick J. A brief review of the International Breast Cancer Intervention Study (IBIS), the other current breast cancer prevention trials, and proposals for future trials. In: Anthony M, Dunn B K, Sherman S, eds. Selective Estrogen Receptor Modulators [SERMs]; Ann N Y Acad Sci 2002; 949: 123-133.
16. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer, hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713-1727.
17. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer, hormone replacement therapy: collaborative reanalysis of data from 51 epidemiology studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997; 350: 1047-1059.
18. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer, breastfeeding: collaborative reanalysis of individual data front 47 epidemiological studies in 30 countries, including 50 302 women with breast cancer and 96973 women without the disease. Lancet 2002; 360: 187-195.
19. Collaborative Group on Hormonal Factors in Breast Cancer. Alcohol, tobacco and breast cancer - collaborative reanalysis of individual data from 53 epidemiology studies, including 58 515 women with breast cancer and 95 067 women without the disease. Br J Cancer 2002; 87: 1234-1245.
20. Robbins A S, Brescianini S, Kelsey J L. Regional differences in known risk factors and the higher incidence of breast cancer in San Francisco. J Natl Cancer Inst 1997; 89: 960-965.
21. van den Brandt P A, Spiegelman D, Yaun S S, Adami H O, Beeson L, Folsom A R, Fraser G, Goldbohm R A, Graham S, Kushi L, Marshall J R, Miller A B, Rohan T, Smith-Warner S A, Speizer Fe, Willett W C, Wolk A, Hunter D J. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol 2000; 152: 514-527.
22. Page D L, Dupont W D. Anatomic markers of human premalignancy and risk of breast cancer. Cancer 1990; 66: 1326-1335.